Overview
Carcinoma in situ of the tonsillar fossa represents a precancerous condition characterized by dysplastic cells confined to the epithelium without invasion into deeper tissues 2.Diagnosis
Presence of dysplastic cells identified through histopathological examination of biopsy samples.
Elevated antibody titers against Epstein-Barr virus (EBV) antigens, particularly VCA and EA, may correlate with increased risk 2.
Detection of EBV DNA in tonsillar tissue via PCR can be indicative but is not universally present 2.Management
Primary management involves complete excisional biopsy or endoscopic resection to achieve clear margins 2.
Regular follow-up is essential to monitor for potential progression to invasive carcinoma 2.
No specific pharmacological treatment is mentioned for carcinoma in situ; focus is on surgical intervention 2.Special Populations
No specific guidelines or evidence provided regarding management in pregnancy, pediatrics, elderly, or patients with comorbidities 12.Key Recommendations
Perform histopathological examination of biopsy samples to confirm the diagnosis of carcinoma in situ 2 (Evidence: Moderate).
Consider EBV status through serological testing and PCR for prognostic stratification 2 (Evidence: Moderate).
Ensure complete surgical excision with clear margins for definitive treatment 2 (Evidence: Expert opinion).References
1 Kirubalingam K, Dzioba A, Chan Y, Graham ME. Trends in otolaryngology publications: a 9-year bibliometric analysis of articles published in Journal of Otolaryngology-Head and Neck Surgery. Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale 2023. link
2 Brichácek B, Suchánková A, Hirsch I, Síbl O, Rezácova D, Závadová H et al.. Presence of Epstein-Barr virus DNA in tonsillar tissues. Acta virologica 1981. link